Given the prognostic and potential therapeutic implications of HSD3B1 genetic status on outcomes, we used the large, ethnically diverse Million Veteran Program (MVP) data set to better inform our understanding of HSD3B1 genetic status in patients with prostate cancer. This evidence concerns the gene HSD3B1 and prostate carcinoma.